Cargando…

Varenicline Solution Nasal Spray: A Review in Dry Eye Disease

Increasing endogenous tear film production via pharmacological neuroactivation of the nasolacrimal reflex [NLR; also known as the trigeminal parasympathetic pathway (TPP)] is a novel therapeutic approach to treating dry eye disease (DED). An intranasal formulation of the water-soluble, small-molecul...

Descripción completa

Detalles Bibliográficos
Autor principal: Frampton, James E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533262/
https://www.ncbi.nlm.nih.gov/pubmed/36197638
http://dx.doi.org/10.1007/s40265-022-01782-4
_version_ 1784802306058878976
author Frampton, James E.
author_facet Frampton, James E.
author_sort Frampton, James E.
collection PubMed
description Increasing endogenous tear film production via pharmacological neuroactivation of the nasolacrimal reflex [NLR; also known as the trigeminal parasympathetic pathway (TPP)] is a novel therapeutic approach to treating dry eye disease (DED). An intranasal formulation of the water-soluble, small-molecule, nicotinic acetylcholine receptor (nAChR) agonist varenicline (Tyrvaya™) has been approved in the USA for the treatment of DED. Twice-daily administration of varenicline solution nasal spray resulted in rapid, statistically significant and clinically meaningful improvements in the signs and symptoms of DED over a period of 4 weeks in two pivotal studies (ONSET-1 and -2). The efficacy of varenicline solution was maintained over a longer-term period of 12 weeks in a third study (MYSTIC). Consistent with the nasal route of delivery, the most common adverse events reported by varenicline solution recipients were non-ocular in nature (mild and transient sneezing and cough). Thus, varenicline solution nasal spray is a rapidly-acting, effective and generally well tolerated treatment for DED that offers several potentially useful advantages over existing topical ocular therapies in terms of increasing endogenous tear secretion and reducing ophthalmic treatment burden. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-022-01782-4.
format Online
Article
Text
id pubmed-9533262
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-95332622022-10-05 Varenicline Solution Nasal Spray: A Review in Dry Eye Disease Frampton, James E. Drugs Adis Drug Evaluation Increasing endogenous tear film production via pharmacological neuroactivation of the nasolacrimal reflex [NLR; also known as the trigeminal parasympathetic pathway (TPP)] is a novel therapeutic approach to treating dry eye disease (DED). An intranasal formulation of the water-soluble, small-molecule, nicotinic acetylcholine receptor (nAChR) agonist varenicline (Tyrvaya™) has been approved in the USA for the treatment of DED. Twice-daily administration of varenicline solution nasal spray resulted in rapid, statistically significant and clinically meaningful improvements in the signs and symptoms of DED over a period of 4 weeks in two pivotal studies (ONSET-1 and -2). The efficacy of varenicline solution was maintained over a longer-term period of 12 weeks in a third study (MYSTIC). Consistent with the nasal route of delivery, the most common adverse events reported by varenicline solution recipients were non-ocular in nature (mild and transient sneezing and cough). Thus, varenicline solution nasal spray is a rapidly-acting, effective and generally well tolerated treatment for DED that offers several potentially useful advantages over existing topical ocular therapies in terms of increasing endogenous tear secretion and reducing ophthalmic treatment burden. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-022-01782-4. Springer International Publishing 2022-10-05 2022 /pmc/articles/PMC9533262/ /pubmed/36197638 http://dx.doi.org/10.1007/s40265-022-01782-4 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, corrected publication 2022Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Adis Drug Evaluation
Frampton, James E.
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
title Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
title_full Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
title_fullStr Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
title_full_unstemmed Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
title_short Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
title_sort varenicline solution nasal spray: a review in dry eye disease
topic Adis Drug Evaluation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533262/
https://www.ncbi.nlm.nih.gov/pubmed/36197638
http://dx.doi.org/10.1007/s40265-022-01782-4
work_keys_str_mv AT framptonjamese vareniclinesolutionnasalsprayareviewindryeyedisease